SI20744B - Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje - Google Patents
Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje Download PDFInfo
- Publication number
- SI20744B SI20744B SI200020021A SI200020021A SI20744B SI 20744 B SI20744 B SI 20744B SI 200020021 A SI200020021 A SI 200020021A SI 200020021 A SI200020021 A SI 200020021A SI 20744 B SI20744 B SI 20744B
- Authority
- SI
- Slovenia
- Prior art keywords
- amino
- methyl
- oxo
- dihydro
- carbonyl
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title claims 2
- 108010044426 integrins Proteins 0.000 title claims 2
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 34
- -1 nitro, amino Chemical group 0.000 claims 31
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 6
- 235000019260 propionic acid Nutrition 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000005309 thioalkoxy group Chemical group 0.000 claims 4
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000006323 alkenyl amino group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- QKZPBAQVDYCGCA-QHCPKHFHSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-[[ethyl(ethylcarbamoyl)carbamoyl]amino]-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound O=C1C(NC(=O)N[C@@H](CC(O)=O)C=2C=CC(C)=CC=2)=C(NC(=O)N(CC)C(=O)NCC)C=CN1CC1=CC=CC=C1Cl QKZPBAQVDYCGCA-QHCPKHFHSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 150000002081 enamines Chemical class 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000005000 thioaryl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- ZRKLOPALDUJTRE-SANMLTNESA-N (3s)-3-[(1-benzyl-6-methyl-2-oxo-4-phenylmethoxypyridin-3-yl)carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C(N(CC=1C=CC=CC=1)C(C)=C1)=O)=C1OCC1=CC=CC=C1 ZRKLOPALDUJTRE-SANMLTNESA-N 0.000 claims 1
- HRQHUYXBRUCBES-FQEVSTJZSA-N (3s)-3-[[1-[(2-bromophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(C)C=CN1CC1=CC=CC=C1Br HRQHUYXBRUCBES-FQEVSTJZSA-N 0.000 claims 1
- CEAOPVIFGJTFDW-SFHVURJKSA-N (3s)-3-[[1-[(2-chloro-6-fluorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(O)C=CN1CC1=C(F)C=CC=C1Cl CEAOPVIFGJTFDW-SFHVURJKSA-N 0.000 claims 1
- ZFKJUHAPJJWBIX-QFIPXVFZSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-2-oxo-4-(propylamino)pyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound O=C1C(NC(=O)N[C@@H](CC(O)=O)C=2C=CC(C)=CC=2)=C(NCCC)C=CN1CC1=CC=CC=C1Cl ZFKJUHAPJJWBIX-QFIPXVFZSA-N 0.000 claims 1
- KZNYVVVWALITCR-QHCPKHFHSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-(4-methylpiperazin-1-yl)-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1CN(C)CCN1C1=C(NC(=O)N[C@@H](CC(O)=O)C=2C=CC(C)=CC=2)C(=O)N(CC=2C(=CC=CC=2)Cl)C=C1 KZNYVVVWALITCR-QHCPKHFHSA-N 0.000 claims 1
- NFFRXLAVOWNYID-QHCPKHFHSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-[2-(2-methoxyethoxy)ethoxy]-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound O=C1C(NC(=O)N[C@@H](CC(O)=O)C=2C=CC(C)=CC=2)=C(OCCOCCOC)C=CN1CC1=CC=CC=C1Cl NFFRXLAVOWNYID-QHCPKHFHSA-N 0.000 claims 1
- WGCGJUIUYDXFGN-IBGZPJMESA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-(3,5-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC(OC)=CC([C@H](CC(O)=O)NC(=O)NC=2C(N(CC=3C(=CC=CC=3)Cl)C=CC=2O)=O)=C1 WGCGJUIUYDXFGN-IBGZPJMESA-N 0.000 claims 1
- JPEASVDUPDPZHB-IBGZPJMESA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-(3,5-dimethylphenyl)propanoic acid Chemical compound CC1=CC(C)=CC([C@H](CC(O)=O)NC(=O)NC=2C(N(CC=3C(=CC=CC=3)Cl)C=CC=2O)=O)=C1 JPEASVDUPDPZHB-IBGZPJMESA-N 0.000 claims 1
- NWPNNXYHAUHECQ-SFHVURJKSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-(3-methylphenyl)propanoic acid Chemical compound CC1=CC=CC([C@H](CC(O)=O)NC(=O)NC=2C(N(CC=3C(=CC=CC=3)Cl)C=CC=2O)=O)=C1 NWPNNXYHAUHECQ-SFHVURJKSA-N 0.000 claims 1
- JNBGWQREIHPHSK-SFHVURJKSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methoxy-3-methylphenyl)propanoic acid Chemical compound C1=C(C)C(OC)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(O)C=CN1CC1=CC=CC=C1Cl JNBGWQREIHPHSK-SFHVURJKSA-N 0.000 claims 1
- LPMXAWSSWLCPMJ-SFHVURJKSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(O)C=CN1CC1=CC=CC=C1Cl LPMXAWSSWLCPMJ-SFHVURJKSA-N 0.000 claims 1
- PAMQUYCMYTUMJW-KRWDZBQOSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound N([C@@H](CC(=O)O)C=1C=C(C=CC=1)C(F)(F)F)C(=O)NC(C1=O)=C(O)C=CN1CC1=CC=CC=C1Cl PAMQUYCMYTUMJW-KRWDZBQOSA-N 0.000 claims 1
- SVJORHDCZSSIIV-KRWDZBQOSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxopyridin-3-yl]carbamoylamino]-3-phenylpropanoic acid Chemical compound N([C@@H](CC(=O)O)C=1C=CC=CC=1)C(=O)NC(C1=O)=C(O)C=CN1CC1=CC=CC=C1Cl SVJORHDCZSSIIV-KRWDZBQOSA-N 0.000 claims 1
- VPUXZZJIKIIVKJ-NRFANRHFSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxoquinolin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(O)C2=CC=CC=C2N1CC1=CC=CC=C1Cl VPUXZZJIKIIVKJ-NRFANRHFSA-N 0.000 claims 1
- JFXXBRDNTIWECS-NRFANRHFSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]carbamoylamino]-3-(3,4-dimethylphenyl)propanoic acid Chemical compound C1=C(C)C(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(C)C=CN1CC1=CC=CC=C1Cl JFXXBRDNTIWECS-NRFANRHFSA-N 0.000 claims 1
- FEUBKIVRGLIYSQ-QFIPXVFZSA-N (3s)-3-[[1-[(2-chlorophenyl)methyl]-4-morpholin-4-yl-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(N2CCOCC2)C=CN1CC1=CC=CC=C1Cl FEUBKIVRGLIYSQ-QFIPXVFZSA-N 0.000 claims 1
- HDTUNALIEDCJGZ-IBGZPJMESA-N (3s)-3-[[4-amino-1-[(2-chlorophenyl)methyl]-2-oxopyridin-3-yl]carbamoylamino]-3-(4-methylphenyl)propanoic acid Chemical compound C1=CC(C)=CC=C1[C@H](CC(O)=O)NC(=O)NC(C1=O)=C(N)C=CN1CC1=CC=CC=C1Cl HDTUNALIEDCJGZ-IBGZPJMESA-N 0.000 claims 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005841 biaryl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- MVHPKFQBHWGTQH-UHFFFAOYSA-N cyano(nitro)carbamic acid Chemical class OC(=O)N(C#N)[N+]([O-])=O MVHPKFQBHWGTQH-UHFFFAOYSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000004986 diarylamino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002084 enol ethers Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13297199P | 1999-05-07 | 1999-05-07 | |
| PCT/US2000/012303 WO2000067746A1 (en) | 1999-05-07 | 2000-05-05 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20744A SI20744A (sl) | 2002-06-30 |
| SI20744B true SI20744B (sl) | 2009-08-31 |
Family
ID=22456441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200020021A SI20744B (sl) | 1999-05-07 | 2000-05-05 | Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1176956B1 (https=) |
| JP (1) | JP5132855B2 (https=) |
| AT (1) | ATE383153T1 (https=) |
| AU (1) | AU5267900A (https=) |
| CA (1) | CA2373360C (https=) |
| CY (1) | CY1107438T1 (https=) |
| CZ (1) | CZ303312B6 (https=) |
| DE (1) | DE60037726T2 (https=) |
| DK (1) | DK1176956T3 (https=) |
| ES (1) | ES2296625T3 (https=) |
| IL (2) | IL146311A0 (https=) |
| IN (1) | IN2001KN01110A (https=) |
| MX (1) | MXPA01011340A (https=) |
| NO (1) | NO324421B1 (https=) |
| NZ (1) | NZ515248A (https=) |
| PL (1) | PL205322B1 (https=) |
| RO (1) | RO122246B1 (https=) |
| RU (1) | RU2263109C2 (https=) |
| SI (1) | SI20744B (https=) |
| SK (1) | SK286696B6 (https=) |
| TR (2) | TR200103178T2 (https=) |
| WO (1) | WO2000067746A1 (https=) |
| ZA (1) | ZA200108774B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
| SI21096B (sl) * | 2001-10-09 | 2012-05-31 | Encysive Pharmaceuticals Inc | Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje |
| RS52392B (sr) * | 2002-02-14 | 2013-02-28 | Pharmacia Corporation | Supstituisani piridinoni kao modulatori p38 map kinaze |
| PE20040728A1 (es) | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| JP2005535710A (ja) | 2002-08-09 | 2005-11-24 | トランス テック ファーマ，インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
| WO2004044046A2 (en) * | 2002-11-08 | 2004-05-27 | Encysive Pharmaceuticals | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds |
| TW200500343A (en) | 2002-12-20 | 2005-01-01 | Vertex Pharma | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| EP1917244A2 (de) | 2005-08-24 | 2008-05-07 | Abbott GmbH & Co. KG | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| CA2680366C (en) * | 2007-03-09 | 2016-06-21 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
| WO2009015485A1 (en) | 2007-08-01 | 2009-02-05 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| AU2010241742A1 (en) * | 2009-04-27 | 2011-11-17 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
| WO2012033548A2 (en) * | 2010-09-07 | 2012-03-15 | E. I. Du Pont De Nemours And Company | Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles |
| CN102596933B (zh) | 2009-09-09 | 2014-09-17 | 杜邦公司 | 除草剂嘧啶酮衍生物 |
| RS55728B1 (sr) * | 2012-01-31 | 2017-07-31 | Daiichi Sankyo Co Ltd | Derivat piridona |
| CN105745206B (zh) | 2013-09-20 | 2019-08-13 | 生物马林药物股份有限公司 | 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂 |
| US20170002077A1 (en) | 2014-03-13 | 2017-01-05 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) * | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| MX2019012699A (es) | 2017-04-28 | 2020-12-11 | Texas Childrens Hospital | Nanoparticulas dirigidas. |
| TWI834634B (zh) * | 2018-02-02 | 2024-03-11 | 美商建南德克公司 | 醫藥化合物、其鹽類、其製劑及其等之製備和使用之方法 |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| KR102908219B1 (ko) | 2019-08-14 | 2026-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2614189A1 (de) * | 1976-04-02 | 1977-10-20 | Hoechst Ag | Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung |
| US5220017A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
| CA2159450C (en) * | 1993-03-31 | 2002-01-08 | Norman Anthony Abood | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors |
| US5534529A (en) * | 1993-06-30 | 1996-07-09 | Sankyo Company, Limited | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| JPH07304755A (ja) * | 1994-05-12 | 1995-11-21 | Yamanouchi Pharmaceut Co Ltd | 縮合ジアゼピン誘導体 |
| US5610296A (en) * | 1994-12-05 | 1997-03-11 | G. D. Searle & Co. | Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| ES2166996T3 (es) * | 1996-05-15 | 2002-05-01 | Searle & Co | Metodo y reactivo para controlar los niveles en sangre de compuestos antiplaquetarios. |
| WO1998011896A1 (en) * | 1996-09-18 | 1998-03-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US6025358A (en) * | 1998-06-11 | 2000-02-15 | G. D. Searle & Co. | Double prodrugs of potent GP IIb/IIIa antagonists |
| US6630488B1 (en) * | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
-
2000
- 2000-05-05 DK DK00937527T patent/DK1176956T3/da active
- 2000-05-05 TR TR2001/03178T patent/TR200103178T2/xx unknown
- 2000-05-05 SK SK1608-2001A patent/SK286696B6/sk not_active IP Right Cessation
- 2000-05-05 DE DE60037726T patent/DE60037726T2/de not_active Expired - Lifetime
- 2000-05-05 MX MXPA01011340A patent/MXPA01011340A/es active IP Right Grant
- 2000-05-05 AT AT00937527T patent/ATE383153T1/de active
- 2000-05-05 RU RU2001133360/04A patent/RU2263109C2/ru not_active IP Right Cessation
- 2000-05-05 AU AU52679/00A patent/AU5267900A/en not_active Abandoned
- 2000-05-05 RO ROA200101210A patent/RO122246B1/ro unknown
- 2000-05-05 ES ES00937527T patent/ES2296625T3/es not_active Expired - Lifetime
- 2000-05-05 TR TR2002/01920T patent/TR200201920T2/xx unknown
- 2000-05-05 EP EP00937527A patent/EP1176956B1/en not_active Expired - Lifetime
- 2000-05-05 IL IL14631100A patent/IL146311A0/xx active IP Right Grant
- 2000-05-05 NZ NZ515248A patent/NZ515248A/xx not_active IP Right Cessation
- 2000-05-05 JP JP2000616772A patent/JP5132855B2/ja not_active Expired - Fee Related
- 2000-05-05 CZ CZ20013963A patent/CZ303312B6/cs not_active IP Right Cessation
- 2000-05-05 PL PL351396A patent/PL205322B1/pl unknown
- 2000-05-05 CA CA2373360A patent/CA2373360C/en not_active Expired - Lifetime
- 2000-05-05 WO PCT/US2000/012303 patent/WO2000067746A1/en not_active Ceased
- 2000-05-05 SI SI200020021A patent/SI20744B/sl not_active IP Right Cessation
- 2000-11-16 IN IN1110KON2001 patent/IN2001KN01110A/en unknown
-
2001
- 2001-10-24 ZA ZA200108774A patent/ZA200108774B/en unknown
- 2001-11-01 IL IL146311A patent/IL146311A/en not_active IP Right Cessation
- 2001-11-06 NO NO20015418A patent/NO324421B1/no not_active IP Right Cessation
-
2008
- 2008-03-05 CY CY20081100253T patent/CY1107438T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20744B (sl) | Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje | |
| SI20876B (sl) | Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje | |
| RU2004110725A (ru) | Гетероциклические производные арилзамещенных пиридинов, использование их в качестве блокаторов натриевых каналов, фармацевтическая композиция | |
| RU2483072C2 (ru) | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 | |
| JP2020500182A5 (https=) | ||
| RU97105769A (ru) | Гетероциклическое производное и лекарственное средство | |
| AR029489A1 (es) | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento | |
| CA2328990A1 (en) | N,n-disubstituted amides that inhibit the binding of integrins to their receptors | |
| HUP0302969A2 (hu) | NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| KR970705545A (ko) | 복소환 유도체 및 의약(heterocyclic derivative and medicine) | |
| KR920002560A (ko) | 살균제 | |
| DK1119567T3 (da) | Quinazolinderivater | |
| CA2369560A1 (en) | Agent for prophylaxis and treatment of liver disease | |
| KR960704865A (ko) | 치환된 이속사졸린, 그의 제조 방법, 그를 함유하는 약제 및 완화제로서 그의 용도 (substituted isoxazolines, process for producing them, agents containing then and their use as safeners) | |
| RU2001112421A (ru) | Бензоилциклогександионы, способ их получения и их применение в качестве гербицидов и регуляторов роста растений | |
| RU2001118466A (ru) | Арил- и гетероциклилзамещенные пиримидиновые производные в качестве антикоагулянтов | |
| ES2141137T3 (es) | Agentes terapeuticos para la enfermedad de parkinson. | |
| KR970704444A (ko) | 트리아진 유도체 및 의약(triazine derivative and medicine) | |
| TR199701647A2 (xx) | �kame edilmi� purin t�revleri,bunlar�n imalat usul� | |
| RU97103983A (ru) | Лекарственные композиции и производные триазина | |
| RU2005111590A (ru) | 2,4-замещенные индолы и их использование в качестве модуляторов 5-гт6 | |
| FR2586679B1 (fr) | Composes heterocycliques, procedes pour leur preparation, et compositions pharmaceutiques les contenant pour inhiber l'enzyme de conversion de l'angiotensine | |
| RU2004129725A (ru) | Новое производное ариламидина или его соль | |
| BR0115516A (pt) | Composição farmacêutica, e, método para prevenir ou tratar hipertensão | |
| EP1553096A4 (en) | pyrazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20090521 |
|
| SP73 | Change of data on owner |
Owner name: ENCYSIVE PHARMACEUTICALS, INC.; US Effective date: 20100216 |
|
| KO00 | Lapse of patent |
Effective date: 20170216 |